Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Kiromic BioPharma stock

Own Kiromic BioPharma stock in just a few minutes.

Updated . What changed?

Fact checked

Kiromic BioPharma, Inc is a biotechnology business based in the US. Kiromic BioPharma shares (KRBP) are listed on the NASDAQ and all prices are listed in US Dollars. Kiromic BioPharma employs 11 staff and has a market cap (total outstanding shares value) of USD$79.3 million.

How to buy shares in Kiromic BioPharma

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Kiromic BioPharma. Find the stock by name or ticker symbol: KRBP. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Kiromic BioPharma reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Kiromic BioPharma, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Kiromic BioPharma. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Kiromic BioPharma share price

Use our graph to track the performance of KRBP stocks over time.

Kiromic BioPharma shares at a glance

Information last updated 2021-02-24.
52-week rangeUSD$8.01 - USD$12.11
50-day moving average USD$9.2601
200-day moving average USD$9.3915
Wall St. target priceN/A
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Kiromic BioPharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Kiromic BioPharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Kiromic BioPharma financials

Gross profit TTM USD$0
Return on assets TTM 0%
Return on equity TTM 0%
Profit margin 0%
Book value N/A
Market capitalisation USD$79.3 million

TTM: trailing 12 months

Shorting Kiromic BioPharma shares

There are currently 4,722 Kiromic BioPharma shares held short by investors – that's known as Kiromic BioPharma's "short interest". This figure is 42.9% up from 3,305 last month.

There are a few different ways that this level of interest in shorting Kiromic BioPharma shares can be evaluated.

Kiromic BioPharma's "short interest ratio" (SIR)

Kiromic BioPharma's "short interest ratio" (SIR) is the quantity of Kiromic BioPharma shares currently shorted divided by the average quantity of Kiromic BioPharma shares traded daily (recently around 26233.333333333). Kiromic BioPharma's SIR currently stands at 0.18. In other words for every 100,000 Kiromic BioPharma shares traded daily on the market, roughly 180 shares are currently held short.

To gain some more context, you can compare Kiromic BioPharma's short interest ratio against those of similar companies.

However Kiromic BioPharma's short interest can also be evaluated against the total number of Kiromic BioPharma shares, or, against the total number of tradable Kiromic BioPharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kiromic BioPharma's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Kiromic BioPharma shares in existence, roughly 0 shares are currently held short) or 0.0014% of the tradable shares (for every 100,000 tradable Kiromic BioPharma shares, roughly 1 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Kiromic BioPharma.

Find out more about how you can short Kiromic BioPharma stock.

Kiromic BioPharma share dividends

We're not expecting Kiromic BioPharma to pay a dividend over the next 12 months.

You may also wish to consider:

Kiromic BioPharma overview

Kiromic BioPharma, Inc., a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. Its product portfolio include ALEXIS AIDT-1, an allogenic CAR cell product candidate targeting AIDT-1; ALEXIS AIDT-2 EOC, an allogenic CAR cell product candidate targeting AIDT-2; ALEXIS AIDT-2 MPM (malignant pleural mesothelioma), an allogenic CAR/NKT-Like cell product candidate targeting AIDT-2; and PD-1-AR, a check point inhibitor for solid tumors, as well as oral healthcare products, such as mouthwash. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site